Objectives: Oral health is grounded in the United National (UN) 2030 Agenda for Sustainable Developement and its 17 Goals (SDGs), in particular SDG 3 (Ensure healthy lives and promote well-being for all at all ages). The World Health Organization (WHO) Global Strategy on Oral Health calls for prioritizing environmentally sustainable and less invasive oral health care, and planetary health. Artificial Intelligence (AI) has the potential to power the next generation of oral health services and care, however its relationship with the broader UN and WHO concepts of sustainability remains poorly defined and articulated. We review the double-edged relationships between AI and oral health, to suggest actions that promote a sustainable deployment of AI for oral health.
Data: Concepts regarding AI, sustainability and sustainable development were identified and defined. A review of several double-edged relationship between AI and SDGs were exposed for the field of Oral Health.
Sources: Medline and international declarations of the WHO, the UN and the World Dental Federation (FDI) were screened.
Study Selection: One the one hand, AI may reduce transportation, optimize care delivery (SDG 3 "Good Health and Well-Being", SDG 13 "Climate Action"), and increase accessibility of services and reduce inequality (SDG 10 "Reduced Inequalities", SDG 4 "Quality Education"). On the other hand, the deployment, implementation and maintenance of AI require significant resources (SDG 12 "Responsible Consumption and Production"), and costs for AI may aggravate inequalities. Also, AI may be biased, reinforcing inequalities (SDG 10) and discrimination (SDG 5), and may violate principles of security, privacy and confidentiality of personal information (SDG 16).
Conclusions: Systematic assessment of the positive impact and adverse effects of AI on sustainable oral health may help to foster the former and curb the latter based on evidence.
Clinical Significance: If sustainability imperatives are actively taken into consideration, the community of oral health professionals should then employ AI for improving effectiveness, efficiency, and safety of oral healthcare; strengthen oral health surveillance; foster education and accessibility of care; ensure fairness, transparency and governance of AI for oral health; develop legislation and infrastructure to expand the use of digital health technologies including AI.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jdent.2022.104344 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Although investment in biomedical and pharmaceutical research has increased significantly over the past two decades, there are no oral disease-modifying treatments for Alzheimer's disease (AD).
Method: We performed comprehensive human genetic and multi-omics data analyses to test likely causal relationship between EPHX2 (encoding soluble epoxide hydrolase [sEH]) and risk of AD. Next, we tested the effect of the oral administration of EC5026 (a first-in-class, picomolar sEH inhibitor) in a transgenic mouse model of AD-5xFAD and mechanistic pathways of EC5026 in patient induced Pluripotent Stem Cells (iPSC) derived neurons.
Drug Development.
Alzheimers Dement
December 2024
National Institute on Aging, NIH, Baltimore, MD, USA.
Background: Epidemiological studies report an elevated risk of neurodegenerative disorders, particularly Parkinson's disease (PD), in patients with type 2 diabetes mellitus (T2DM) that is mitigated in those prescribed incretin mimetics or dipeptidyl peptidase 4 inhibitors (DPP-4Is). Incretin mimetic repurposing appears promising in human PD and Alzheimer's disease (AD) clinical trials. DPP-4Is are yet to be evaluated in PD or AD human studies.
View Article and Find Full Text PDFDrug Development.
Alzheimers Dement
December 2024
Merry Life Biomedical Company, Ltd., Tainan City, Taiwan, Taiwan.
Background: Alzheimer's disease (AD) is complex in pathogenesis and related to aging biology, especially in late-onset AD. We identified a novel synthetic curcumin analog TML-6 through the platform of 6 biomarkers of anti-aging, anti-inflammation, and anti-Aβ as the potential AD drug candidate. TML-6 exhibits multi-target effects on AD pathogenesis, including the activation of NrF-2, the regulation of autophagic machinery through mTOR, the inhibition of APP synthesis and reduction of Aβ, the upregulation of ApoE, and the inhibition of microglial activation.
View Article and Find Full Text PDFBackground: VG-3927 is a highly potent, selective, brain penetrant, oral small molecule TREM2 agonist that is currently under development for the treatment of Alzheimer's disease (AD). TREM2, a receptor expressed on microglia in the brain is critical to microglial function in health and in disease. Among microglia-associated AD risk genes, partial loss-of-function variants of TREM2 confer 2-3 fold increase in risk for developing AD, motivating efforts to identify pharmacological agonists targeting TREM2 as a therapeutic option.
View Article and Find Full Text PDFDementia Care Research and Psychosocial Factors.
Alzheimers Dement
December 2024
Music and Health Science Research Collaboratory, University of Toronto, ON, Canada.
Background: The dual-cyclical relationship between language and cognition, encapsulated in linguistic relativity, underscores the reciprocal influence of thoughts on communication and vice-versa. This study explores the intricate changes in pragmatics, a fundamental aspect of human communication, during the aging process, considering changes in sensory abilities, cognition, and language.
Method: Sixty participants, aged ≥50 years with a minimum of five years of formal education, were included, excluding those with neurological or psychological illnesses.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!